Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X:
“1L osimertinib early PD: EGFRm NSCLC, RWD (n=1488)
- rwPFS 16.3, mOS 36.7 mo
- TP53mut aHR 1.68 ex19del vs 1.18 L858R (p=0.2)
- PD-L1: top very-early PD predictor.
Who skips osimertinib monotherapy for FLAURA2 or MARIPOSA?”
Title: Clinicogenomic determinants of early progression on first-line osimertinib in EGFR-mutant NSCLC
Authors: Federica Pecci, Mark Y. Jeng, Alessandro Di Federico, Emanuele Mazzola, Marianna Peroni, Federico Monaca, Emanuele Claudio Mingo, Lodovica Zullo, Daniele Marinelli, Andrea Torchia, Francesca Colamartini, Silvia Teresa Riva, Minh Tri Le, Ayesha Aijaz, Maisam Makarem, Eleonora Gariazzo, Biagio Ricciuti, Valentina Santo, Mihaela Aldea, Edoardo Garbo, Francesco Paoloni, Ilit Turgeman, Igor Gomez-Randulfe, Andrea De Giglio, Irene Zannini, Sara Stumpo, Francesco Mantuano, Alessandro Leonetti, Michela Verzè, Roberta Minari, Marco Russano, Francesco Facchinetti, Seshiru Nakazawa, Cassio Murilo Hidalgo-Filho, Stefano Scalera, Marcello Maugeri-Saccà, Amanda Pupo, Stacey Frumm, Xinan Wang, Molly Bogardus, Jose Avila, Raphael Liautaud, Sara Baglivo, Danielle Haradon, Mizuki Nishino, Igor Odintsov, Lynette M. Sholl, Ullas Batra, Nishant Gandhi, Marzia Capelletti, Andrew Elliott, Joe Murray, George Sledge, Soo-Ryum Yang, Julia Rotow, Jaclyn LoPiccolo, Abdul Rafeh Naqash, Mark M. Awad, Antoine Desilets, Benjamin Besse, David Planchard, Alessio Cortellini, Roberto Ferrara, Giulio Metro, Federico Cappuzzo, Raffaele Califano, Andrea Ardizzoni, Marcello Tiseo, Helena Yu, Pasi A. Jänne.
Read the full article in the Journal of Thoracic Oncology.
You can also explore:
- FLAURA2: Early EGFR ctDNA Clearance Is Prognostic, Not Predictive, for Osimertinib-Chemotherapy Benefit
- MARIPOSA: Amivantamab Plus Lazertinib Reduces EGFR/MET Resistance and Extends Second-Line Disease Control in EGFR-Mutated NSCLC
